Jefferies Upgrades Teva Pharmaceutical Indus to Buy, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Glen Santangelo upgraded Teva Pharmaceutical Industries (NYSE:TEVA) from Hold to Buy and increased the price target from $10 to $14, indicating a positive outlook on the company's stock.
January 23, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies upgraded Teva Pharmaceutical from Hold to Buy and raised the price target from $10 to $14, suggesting a bullish stance on the stock.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect a change in the analyst's view on the company's future performance. The increase in price target from $10 to $14 represents a significant potential upside, which could attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100